RELAPSED B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RELAPSED B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immune cell therapy trial targets Tough-to-Treat lymphoma
Disease control Recruiting nowThis study is testing a new combination of three drugs for adults whose B-cell non-Hodgkin lymphoma has come back or stopped responding to standard treatments. The treatment involves a short course of chemotherapy followed by infusions of engineered immune cells (CD19 t-haNK), an…
Matched conditions: RELAPSED B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug cocktail tested for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study aims to find a safe and effective dose for a new combination of cancer drugs. It is for adults whose B-cell non-Hodgkin lymphoma has come back or has not responded to at least two prior treatments. Researchers will test an approved drug, loncastuximab tesirine, alongsi…
Matched conditions: RELAPSED B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC